A LEGACY OF ACHIEVEMENT,

TOWARDS A FUTURE OF ACCOMPLISHMENT

Mahesh Karande | President & CEO, Board Director

Mahesh Karande is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization and product life cycle management stages. His breadth of therapeutic experience spans cardiovascular and metabolic, oncology, neurosciences, ophthalmology, antibiotics, pain, respiratory and rare and genetic diseases as well as drug and device combinations. He has been involved with more than 10 product launches in the U.S. and across global markets.

He has strong leadership, operational and business-building experiences combined with a global work history spanning the U.S., Europe, Asia and Africa.

Prior to taking the helm at Omega, Mr. Karande was President and CEO of Macrolide Pharmaceuticals, a company he took from discovery into early development. Earlier, Mr. Karande spent several years at Novartis in senior leadership roles: VP and Head of US Oncology for solid tumors, President of Novartis Africa and President of Novartis Egypt. He worked for McKinsey & Company prior to joining the bio-pharmaceutical industry. Mr. Karande currently serves on the Board of Directors of KSQ Therapeutics.

Mr. Karande has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology where he completed his M.S. in engineering and the University of Bombay where he completed undergraduate studies in engineering.

Dr. Thomas McCauley joined Omega as chief scientific officer in August 2019. Prior to Omega, he served as CSO at Zikani Therapeutics (formerly Macrolide Pharmaceuticals) and before that at Translate Bio (formerly RaNA Therapeutics).

In these roles, Dr. McCauley was responsible for overall scientific vision, strategic direction and leadership of research and development. He provided scientific, technical and operational oversight for advancement of the company’s oligo, mRNA and novel macrocyclic technology platforms and management of portfolio therapeutic programs in pulmonary, metabolic, genetic and infectious disease.

Previously, Dr. McCauley served as vice president and head of Global Nonclinical Development at Shire Pharmaceuticals, where he made significant contributions to the development and global approvals of many of Shire's products, including Replagal® for Fabry disease, Vpriv® for Gaucher disease, Elaprase® for Hunter syndrome, Firazyr® for hereditary angioedema and Xiidra® for dry eye disease.

Dr. McCauley has more than 19 years of experience in the biotechnology and pharmaceutical industries and has authored more than 40 scientific publications, book chapters and patents. He holds undergraduate and graduate degrees from Cornell University and received his Ph.D. from the University of Alabama at Birmingham.

Yan Moore, M.D. | Chief Medical Officer

Dr. Yan Moore joined Omega as Chief Medical Officer in January 2022. Prior to Omega, he served as Senior Vice President, Head of Oncology Therapeutic Area at Ipsen Pharmaceuticals, and before that as Chief Medical Officer and Senior Vice President of Clinical Development and Research and Development at Anchiano Therapeutics (previously BioCanCell Therapeutics).

In these roles, Dr. Moore was responsible for identifying and executing research and development objectives in areas of oncology and immune-modulatory therapies, managing clinical and preclinical drug development (pre-IND to phase 1), scientific and development strategy, creation of internal drug development engines to support the overall portfolio strategies, and managing global medical affairs strategy.   

Previously, Yan held several senior roles of increasing responsibility at Ariad Pharmaceuticals, Sanofi Oncology, GlaxoSmithKline, BMS amongst others. As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.

Dr. Moore has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Moore received his medical degree and Bachelor of Medical Sciences from the Sackler School of Medicine at Tel Aviv University, Master of Business Administration from the LeBow College of Business at Drexel University and completed the Advanced Management Program at Harvard Business School.

Joshua Reed | Chief Financial Officer

Joshua Reed joined Omega as Chief Financial Officer in May 2022 with over 25 years of successful and diverse corporate and financial operations experience. Prior to Omega, Mr. Reed most recently served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. During his time at Aldeyra, Mr. Reed led multiple capital raises, oversaw the company's interactions with current and prospective investors and managed all aspects of the company's financial processes, including quarterly and annual SEC filings..

Previously, Mr. Reed held a variety of finance roles of increasing responsibility at Bristol-Myers Squibb, most recently serving as Vice President and Head of Finance Operations for the United States and Puerto Rico. While at Bristol-Myers Squibb, Mr. Reed also led financial planning and analysis, supply chain and manufacturing finance, and worked on various acquisitions, divestitures, alliances, and collaboration agreements. Prior to joining the bio-pharmaceutical industry, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed began his career at JP Morgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed currently serves on the Board of Directors and as Chairman of the Audit Committee of Scholar Rock, a publicly traded biotechnology company.

Mr. Reed received his Bachelor of Science in Finance from Rutgers University and his Master of Business Administration from the University of Michigan’s Ross School of Business.

Ling Zeng, Esq. | Chief Legal and Administrative Officer

Ling Zeng joined Omega as Chief Legal and Administrative Officer in March 2022. Prior to joining Omega, Ling was most recently Chief Legal Officer and Secretary of Dicerna Pharmaceuticals, where she worked alongside other executives, the board of directors and their committees to develop and implement company strategy, policy, governance and compliance. Earlier, Ms. Zeng served as Deputy Head Legal, Group Mergers and Acquisitions, at Novartis AG, where she was responsible for global transactions across the Novartis Group.

Ms. Zeng brings over 20 plus years of experience in the healthcare industry. Previously, she held various legal executive roles of increasing responsibility at Bausch Health Companies, Inc., Penwest Pharmaceuticals Co. and Barr Laboratories, Inc. In these roles, Ms. Zeng was responsible for providing sound counsel on public company governance, compliance, enterprise risk management, development and commercial operations, strategic transactions, healthcare industry regulations, and IP portfolio management and strategy. Ms. Zeng began her legal career at Cleary, Gottlieb, Steen and Hamilton and, prior to that, also spent time as a researcher at Alkermes Inc. and LeukoSite Inc.

Ms. Zeng received her Bachelor of Science in Physics from Peking University, Master of Science in Biophysics from Brandeis University, and Juris Doctor in Law from Georgetown University.

Barbara Chan | SVP, Finance

Barbara Chan brings over 20 years of experience as a senior finance leader in the biotechnology, pharmaceutical and life sciences industries to Omega. Prior to joining the Omega team, Barbara most recently served as Vice President of Finance and Chief Accounting Officer of Aegerion Pharmaceuticals.

Joining Aegerion at a particularly challenging time, Ms. Chan was able to completely transform and rebuild the finance organization, including significantly reducing the finance team turnover, establishing an appropriate control environment, improving internal processes, and enhancing both internal and external reporting. During her tenure at the company, Ms. Chan helped to support in the resolution of the significant legal and compliance issues facing the company, and led her team through a complex merger, two product launches outside of the U.S., and played a pivotal role in the ultimate sale of the company.

Prior to that, Ms. Chan spent 13 years with Parexel International, where she oversaw the company’s revenue growth from $320 million to over $2 billion. While at Parexel, she held roles of increasing responsibility, most recently as Global Head of Accounting Services.

Ms. Chan is a CPA with a B.S. in Accountancy and an M.S. in Taxation from Bentley University.

Sivakesava Sakhamuri, Ph.D. | SVP, Head of Technical Operations and Quality

Siva Sakhamuri brings over 25 years of successful pharmaceutical manufacturing experience and leadership in bringing innovative medicines to patients. Mr. Sakhamuri has broad experience in clinical and commercial biologics, small molecule and vaccine manufacturing, CMC strategy, process development, external vendor/alliance and project management, regulatory support and life cycle product management. 

Prior to joining Omega, Siva was Head of Manufacturing for Alnylam’s internal and external manufacturing operations, including seminal contributions to the registration and launch of Onpattro^®, Givlaari^® and Oxlumo^®. Before Alnylam, Siva was Executive Director, Global Tech Services, Process and Analytical Development at Alexion Pharmaceuticals, and earlier was Director, Manufacturing for Sanofi-Pasteur, where he was responsible for commercial vaccine product manufacturing and facility management. Siva began his industry career at Bristol-Myers Squibb Co. supporting global biologics manufacturing teams.

Siva received his Ph.D. degree in Biochemical Engineering from Indian Institute of Technology, completed a Postdoctoral Fellowship at the Korea Research Institute of Bioscience & Biotechnology, and additional Postdoctoral research at Hong Kong University of Science and Technology and Pennsylvania State University. 

Ramola Bhandarkar  | VP, Regulatory Affairs

Ramola Bhandarkar joined Omega as Vice President of Regulatory Affairs and brings over 20 years of experience in the biopharmaceutical industry working with a diverse range of therapeutics including cellular therapies, monoclonal antibodies, antibody drug conjugates, and small molecules.

Most recently, she was the Head of Regulatory Strategy for bluebird bio’s Oncology Business Unit and contributed toward building that team. She was responsible for providing strategic regulatory expertise for both early and late phase cellular therapy and gene-edited programs. During her time at bluebird bio, she was the bluebird bio global regulatory lead for ABECMA^®, which recently earned the distinction of becoming the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Prior to bluebird bio, Ramola held positions of increasing responsibility at ImmunoGen, Inc. where she led the clinical regulatory group which provided regulatory guidance for a number of early and late phase antibody drug conjugates to treat cancer. Earlier in her career, Ramola spent many years at Cephalon (now Teva Pharmaceuticals) and Organon, Inc. in pharmaceutical development.

Ramola received her M.S., Quality Assurance/Regulatory Affairs from Temple University, her M.S., Pharmaceutical Sciences from University of Missouri-Kansas City, and her Bachelor of Pharmacy from Pune University, India.

Lisamarie Fahy | VP, Clinical Development Operations

Lisamarie Fahy brings over 30 years of clinical experience, including expertise in clinical trial management and delivering high quality clinical development programs through global registration and approval, regulatory submissions with the FDA, EMEA and PMDA, marketing approvals and GCP compliance and inspections. Her experience spans both academic and industry settings with expertise in gene therapy, cardiovascular, oncology and rare disease programs.

Most recently, Ms. Fahy was Vice President, Head of Clinical Development Operations at AVROBIO.  Prior to AVROBIO, she served as Head of Global Clinical Development Operations at both H3 Biomedicine and Aegerion Pharmaceuticals. She also held various clinical development roles of increasing responsibility at Shire Pharmaceuticals and Wyeth Research. Ms. Fahy began her career as a clinical research and program coordinator at the Brigham and Women’s Hospital.

Ms. Fahy received an B.S. in Physiology from the University of Massachusetts.  

Joe Newman, Ph.D. | VP, Biology

Dr. Joe Newman has over 20 years of experience leading and supporting all stages of drug development, from lead optimization through to clinical development. Prior to joining Omega, Joe was Vice President of Early Development at Zikani Therapeutics, where he successfully transitioned the company’s focus from infectious diseases to oncology and rare diseases.

Prior to Zikani, he was the head of Biology at Tetraphase Therapeutics, leading the NDA and MAA submissions for Xerava^®. Before that, Dr. Newman spent ten years at AstraZeneca in various roles supporting early development and IND submissions for a number of programs, including two products currently in Phase 3 clinical development.

Dr. Newman received his undergraduate degree in Biology from the University of Delaware, his Ph.D. in Molecular Microbiology from the University of Rhode Island and completed fellowships at Tufts Medical School and MIT.

Charles O’Donnell, Ph.D. | VP, Head of Computational Genomics and Data Sciences

Dr. Charles O’Donnell brings over 15 years of data science and genomics experience to Omega, with an extensive background using data to solve scientific problems, specifically in genetic medicines. He has successfully led multi-disciplinary teams and has proven a broad range of technical and strategic expertise across data science, computational biology, machine learning, genomics and epigenomics, NGS, editing, gene therapy, proteomics, systems and network analysis, high performance computing, and data integration.

Prior to joining Omega, Charles was Head of the Computational Biology and Data Sciences function at Evelo Biosciences, and the first Head of Computational Biology and Data Sciences at Camp4 Therapeutics. Earlier in his career, he was the computational subject-matter expert in Biogen’s Epigenetics and Cell and Gene Therapy team and worked as a joint NRSA Postdoctoral Fellow in the Melton Lab of Harvard’s Stem Cell Institute and the Gifford Lab of MIT’s Computer Science and AI Laboratory.

Dr. O’Donnell received his Ph.D. in Electrical Engineering and Computer Science from MIT, working in the Berger and Devadas Labs at MIT’s Computer Science and AI Laboratory and the Lindquist Lab of the Whitehead Institute. He received his M.S. in Electrical Engineering and Computer Science from MIT and his B.S. in Computer Engineering from Columbia University.

Samir Padalkar, Ph.D  | VP, Data and IT

Dr. Samir Padalkar  joined Omega Therapeutics as Vice President of Data and IT bringing over 30 years of distributed real-time and data science experience with an extensive background in healthcare, financial trading, process control, and IoT. He is an industry leader in Big Data/AI-ML technology application with proven success in creating digital innovations across varying industries.

Prior to joining Omega, Samir founded Numeric Trails; a company that focused on providing data, analytics and computational expertise to leading organizations such as NYC Dept. of Health, Sumitomo Mitsui, and Honeywell. Earlier in his career, he worked in several securities exchange and financial businesses such as HOLD Brothers and Tradeweb. Samir began his career at a startup, Quant Trading, which developed one of the first off-the-shelf real-time fixed income & derivatives trading system, and was eventually acquired by Thomson Financial.

Dr. Samir Padalkar received his M.S. and Ph.D. in Electrical Engineering from Vanderbilt University, working in the distributed real-time systems lab that later became the Institute for Software Integrated Systems. He received his B.Tech. in Electronics Engineering from the Indian Institute of Technology – Madras.